Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour

Sara Elena Rebuzzi, Massimiliano Grassi, Fabio Catalano, Michele Buscaglia, Rossella Bertulli, Camilla Satragno, Liliana Belgioia, Danila Comandini

Research output: Contribution to journalArticlepeer-review


Tenosynovial giant cell tumour (TGCT) is a group of rare soft tissues neoplasia affecting synovial joints, bursae and tendon sheaths and is classified as localized type or diffuse type. The diffuse type (TGCT-D), also known as 'pigmented villonodular (teno)synovitis' is characterized by local aggressivity, with invasion and destruction of adjacent soft-tissue structures, and high local recurrence rate. Radical surgery remains the standard therapy while adjuvant radiotherapy may help to control local spread. Malignant TGCT is characterized by high rate of local recurrences and distant metastasis. Few cases of malignant TGCT and very few evidences on systemic therapies are described in the literature, so, to date, no systemic treatment is approved for this rare disease. We report the case of a malignant TGCT patient treated with many different systemic therapies, including chemotherapy and tyrosine-kinase inhibitors, and performed a review of the literature on the systemic treatment options of this rare tumour.

Original languageEnglish
Pages (from-to)80-84
Number of pages5
JournalAnti-Cancer Drugs
Issue number1
Publication statusPublished - Jan 1 2020

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour'. Together they form a unique fingerprint.

Cite this